NASDAQ:ATHA

Biotechnology·Investment·NASDAQ:ATHA·News·Pharmaceuticals

LeonaBio Gets $20 Price Target Ahead of June Pipeline Test

Piper Sandler initiated coverage of LeonaBio with an overweight rating and a $20 price target. Shares rose 1.45% to $9.81 on volume just over 51,000. LeonaBio will present ALS drug ATH-1105 on June 3 and join an oncology trials panel June 24. Phase 3 enrollment for breast cancer drug lasofoxifene is expected to finish in late 2026.

May 28, 2026

Peet Outlook Upgrade Boosts Housing Sector Interest
May 28, 2026, 4:56 AM EDT. Peet Limited received an outlook upgrade, sparking renewed interest in the housing market growth sector. The upgrade reflects confidence in Peet's prospects amid rising demand for residential developments. Analysts cited strong project pipelines and improving market conditions as key drivers. The housing sector, crucial for economic recovery, could see increased investment flow following Peet's positive forecast. Investors are watching closely for potential gains as Peet advances its development strategy.